Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
(Reuters) – Shares of Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna, slumped 32% in their Nasdaq debut on Friday. The stock opened for trading at $10.25 compared with the IPO price of $15 per share. The lukewarm debut, which gives Metagenomi a valuation of $384 million, underscores the unpredictability young…